ejobkar Monday, 12/09/19 10:04:06 PM Re: None Post # of 759 New Delivery System Designed to Enable Home Care Therapy "BioVie’s new patent-pending formulation of terlipressin has demonstrated the potential for room-temperature storage. If extended room-temperature product stability can be shown, this feature could provide another key product advantage. To the best of the Company’s knowledge, all other terlipressin products sold globally must be stored under refrigeration and there are no prefilled syringe formats available for treating patients." "In addition, the Company has a pending patent application covering the proprietary liquid formulation of terlipressin to be used in its planned Phase 2b/3 trial, subject to FDA clearance. This could eventually provide up to 20 years of patent coverage in each country for which the Company seeks patent protection, including the US, according to the patent laws of that country."